Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $355

Barclays analyst Geoff Meacham maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $333 to $355.
byBenzinga Newsdesk
July 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Geoff Meacham maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $333 to $355.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Housing Market Bottoms Out Per JPMorgan’s Initiation Of Redfin, Zillow

By AJ Fabino
February 27, 11:32 AM
Last summer, Federal Reserve chair Jerome Powell laid out a plan to reset the U.S. housing market, which has been putting the squeeze on aspiring homeowners. How? By increasing interest rates, and subsequently spiking mortgage rates.

JPM